Introduction
Methods
Study population
Definition of CAD
Laboratory tests
EAT volume measurement with multislice CT
Statistical analyses
Results
Patient characteristics
Dapagliflozin (N = 20) | Conventional therapy (N = 20) | p value | |
---|---|---|---|
Age (years) | 68 ± 4 | 66 ± 6 | 0.30 |
Male/female (n) | 16/4 | 14/6 | 0.48 |
Body weight (kg) | 71.4 ± 14.4 | 69.5 ± 12.2 | 0.37 |
BMI | 26.6 ± 4.6 | 25.0 ± 3.1 | 0.25 |
Hypertension | 14 (70) | 12 (60) | 0.52 |
Smoking, ever | 6 (30) | 5 (25) | 0.73 |
Lipid profile | |||
LDL (mg/dl) | 91 ± 26 | 84 ± 20 | 0.44 |
TG (mg/dl) | 152 ± 92 | 151 ± 81 | 0.83 |
HDL (mg/dl) | 46 ± 14 | 40 ± 10 | 0.17 |
TG/HDL | 3.6 ± 2.1 | 3.7 ± 2.1 | 0.73 |
Glycemic marker | |||
HbA1c (%) | 7.2 ± 0.6 | 7.4 ± 1.1 | 0.51 |
FBS (mg/dl) | 144 ± 41 | 136 ± 24 | 0.48 |
HOMA-IR | 2.6 ± 1.9 | 2.5 ± 1.8 | 0.79 |
iHOMA 2%S | 113 ± 94 | 134 ± 75 | 0.52 |
Keton body (μmol/l) | 126 ± 116 | 120 ± 105 | |
Adipose-associated marker | |||
EAT volume (cm3) | 115 ± 22 | 108 ± 25 | 0.38 |
TNF-α (pg/ml) | 2.4 ± 0.7 | 2.2 ± 0.7 | 0.78 |
PAI-1 (ng/ml) | 42.2 ± 16.1 | 45.7 ± 14.6 | 0.41 |
BNP (pg/ml) | 82 ± 88 | 102 ± 129 | 0.62 |
Alb/Cre ratio (mg/g CRE) | 21 ± 39 | 38 ± 68 | 0.50 |
Dapagliflozin | Conventional therapy | |
---|---|---|
α-GI | 2 (10) | 1 (5) |
DPP-4 inhibitor | 5 (25) | 6 (30) |
Biguanide | 6 (30) | 5 (25) |
Sulfonyl urea | 2 (10) | 1 (5) |
Glinide | 0 (0) | 0 (0) |
Pioglitazone | 1 (5) | 0 (0) |
Dapagliflozin (n = 20) | Conventional therapy (n = 20) | |
---|---|---|
SGLT-2 inhibitor | 20 (100) | 0 |
α-GI | 0 (0) | 3 (15) |
DPP-4 inhibitor | 0 (0) | 14 (70) |
Biguanide | 0 (0) | 1 (5) |
Sulfonyl urea | 0 (0) | 1 (5) |
Glinide | 0 (0) | 1 (5) |
Pioglitazone | 0 (0) | 0 |
Changes in body weight and laboratory data (Table 4)
Dapagliflozin (n = 20) | Conventional therapy (n = 20) | p value, dapagliflozin vs. conventional | |
---|---|---|---|
Δ body weight (kg) | − 2.9 ± 3.4** | 0.2 ± 2.4 | 0.01 |
Lipid profile | |||
ΔLDL (mg/dl) | 6.0 ± 26.5 | − 1.0 ± 13.7 | 0.41 |
ΔTG (mg/dl) | − 33.4 ± 66.2* | 3.2 ± 19.0 | 0.07 |
ΔHDL (mg/dl) | 5.1 ± 15.2 | − 0.7 ± 4.8 | 0.21 |
ΔTG/HDL | − 0.8 ± 1.7** | 0.2 ± 0.8 | 0.06 |
Glycemic marker | |||
ΔHbA1c (%) | − 0.41 ± 0.21** | − 0.19 ± 0.25 | 0.22 |
ΔHOMA-IR | − 0.99 ± 1.90** | − 0.42 ± 0.86* | 0.64 |
ΔiHOMA2%S | 65.7 ± 70.9** | 42.2 ± 61.1 | 0.36 |
ΔBNP (pg/ml) | − 24 ± 83 | − 12 ± 54 | 0.68 |
ΔAlb/Cre (mg/g·CRE) | − 3.8 ± 29.6 | 8.7 ± 43.2 | 0.38 |
Changes in adipose-associated markers (Table 5)
Dapagliflozin (n = 20) | Conventional therapy (n = 20) | p value, dapagliflozin vs. conventional | |
---|---|---|---|
ΔEAT volume (cm3) | − 16.4 ± 8.3** | 4.7 ± 8.8 | 0.01 |
ΔTNF-α (pg/ml) | − 0.5 ± 0.7** | 0.03 ± 0.3 | 0.03 |
ΔPAI-1 (ng/ml) | − 10.1 ± 18.8* | − 2.0 ± 9.7 | 0.18 |